Cemiplimab, Fianlimab

3 trials 3 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

1 Sponsors

10 Countries

Phase II

Phase I (FiH)

Phase II: 2 Phase I (FiH): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Fallopian tube cancer 1 Peritoneal cancer index 1 Ovarian cancer recurrent 1 Non-small cell lung cancer 1 Malignant melanoma 1

Sponsors using this IMP

Regeneron Pharmaceuticals Inc. 3

All trials

3 total

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Phase II 5 countries Regeneron Pharmaceuticals Inc.
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4… Recruiting

2022-502825-17-00 Phase II 8 countries Regeneron Pharmaceuticals Inc.
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting

2022-501904-83-00 Phase I (FiH) 3 countries Regeneron Pharmaceuticals Inc.

Showing 1–3 of 3 trials

← All drugs A–Z